Clinical Trials · NCT02396953

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Name: Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1/Phase 2Lanreotide Octreotide

Phase: Phase 1/Phase 2
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 28
Start date: Mar 2015
Locations: 36 sites, 12 countries
Primary endpoint: Determination of the Maximum Tolerated Dose (MTD) by Number of Subjects With DLTs.

View Lanreotide compound reference